Sibrotuzumab is a monoclonal antibody designed for therapeutic use, primarily targeting specific proteins associated with certain types of cancer. As a biologic agent, it is characterized by its ability to bind selectively to its target, which can inhibit tumor growth or promote immune-mediated destruction of cancer cells. The chemical structure of Sibrotuzumab includes a complex arrangement of amino acids that form its variable and constant regions, essential for its specificity and function. It is typically administered via injection and may be used in combination with other treatments to enhance efficacy. The pharmacokinetics of Sibrotuzumab involve its distribution, metabolism, and excretion, which are crucial for determining dosing regimens and potential side effects. As with many monoclonal antibodies, common side effects may include infusion reactions, immune-related adverse events, and potential impacts on organ systems. Ongoing clinical trials and research continue to evaluate its effectiveness and safety profile in various cancer types.

Sibrotuzumab

216669-97-5: Sibrotuzumab is a monoclonal antibody designed for therapeutic use, primarily targeting specific proteins associated with certain types of cancer. As a biologic agent, it is characterized by its ability to bind selectively to its target, which can inhibit tumor growth or promote immune-mediated destruction of cancer cells. The chemical structure of Sibrotuzumab includes a complex arrangement of amino acids that form its variable and constant regions, essential for its specificity and function. It is typically administered via injection and may be used in combination with other treatments to enhance efficacy. The pharmacokinetics of Sibrotuzumab involve its distribution, metabolism, and excretion, which are crucial for determining dosing regimens and potential side effects. As with many monoclonal antibodies, common side effects may include infusion reactions, immune-related adverse events, and potential impacts on organ systems. Ongoing clinical trials and research continue to evaluate its effectiveness and safety profile in various cancer types.

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP).Sibrotuzumab is used in the study of colorectal

Humanized monoclonal antibody targeting FAP; cancer treatment

CAS 216669-97-5

Sibrotuzumab

Sibrotuzumab

Ref: TM-T76792

Sibrotuzumab

Ref: 3D-CLA1215